Eli Lilly and Company have announced a price reduction for Zepbound single-dose vials for self-paying patients using LillyDirect, the company’s direct-to-consumer (DTC) platform.

The price reduction is part of an ongoing effort to lower out-of-pocket costs for patients diagnosed with obesity in the U.S.¹

“Far too many people who need obesity treatments still face cost and coverage barriers, Today’s action underscores Lilly’s commitment to improving access across the obesity care landscape,” Ilya Yuffa, executive vice president and president, Lilly U.S. and global customer capabilities, said in a press release. “We will keep working to provide more options, expanding choices for delivery devices and creating new pathways for access, so more people can get the medicines they need.”

Lilly’s new Zepbound single-dose vial pricing

With the new price adjustments, patients with a valid prescription can now access Zepbound’s initial single-dose vial (2.5 mg) for $299 a month, a $50 price reduction, via the LillyDirect Zepbound Self Pay Journey Program.¹ Patients will also be offered a new price for the 5 mg single-dose vial for $399 a month, a $100 reduction to its original price.

Additionally, Lilly is reducing the price of its 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses to $449 per month from its original $499 per month price.¹

The LillyDirect platform facilitates access to medications by connecting patients with independent telehealth providers and other disease management resources, bypassing the need to obtain a prescription from a physician and then going to a pharmacy to fill it.

Earlier this year, Lilly announced a partnership with Walmart Pharmacy, offering the first retail pick-up option for its DTC priced Zepbound single-dose vials. The partnership grants customers the ability to have their prescriptions routed directly to LillyDirect’s Self Pay Pharmacy Solutions through their respective health care provider’s electronic health record system and also gives patients an additional option for delivery.

LillyDirect Pharmacy Solutions is powered by third party online pharmacy fulfillment services to provide patients with consistent access to prescribed medications via home delivery.

Novo Nordisk reduces prices for Wegovy and Ozempic

Eli Lilly isn’t the only company adjusting its GLP-1 medication prices, as Novo Nordisk recently announced a limited time promotion offering a reduced introduction price for its flagship GLP-1 medications Wegovy and Ozempic.

Novo Nordisk’s introductory offer provides new self-pay patients the opportunity to purchase either Wegovy or Ozempic injectables for a reduced price of $199 per month for the initial first two months of therapy, which can be applied to either the 0.25 mg or 0.5 mg dose amounts of either medication.

"As pioneers of the GLP-1 class, we are committed to ensuring that real, FDA-approved Wegovy and Ozempic are affordable and accessible to those who need them," commented Dave Moore, Novo Nordisk’s EVP of U.S. operations, in a press release. "The US healthcare system is complex, with different types of insurance and various ways for patients to obtain their medicines. Our new savings offers provide immediate impact, bringing forward greater cost savings for those who are currently without coverage or choose to self-pay. It is part of a larger strategy to expand access that includes building relationships with telehealth providers and major retailers, expanding coverage, and working with the Administration to lower costs for people living with chronic diseases like obesity and type 2 diabetes."

Sources

1. Lilly lowers the price of Zepbound® (tirzepatide) single-dose vials Eli Lilly and Company December 1, 2025 https://investor.lilly.com/news-releases/news-release-details/lilly-lowers-price-zepboundr-tirzepatide-single-dose-vials